Summary
Samsung Medison, a medical device unit of Samsung Electronics, has announced its plans to acquire Sonio, a Paris-based startup that develops AI-powered software for ultrasound workflows. The acquisition, valued at about 92.7 million KRW (approximately $126 million), will allow Samsung Medison to enhance its AI-driven imaging capabilities. Sonio’s software is designed to assist obstetricians and gynecologists in evaluating and documenting ultrasound exams, and it has received regulatory clearance from the US FDA. Despite the acquisition, Sonio will continue to operate independently.
Key Points
– Samsung Medison, a subsidiary of Samsung Electronics, will acquire Paris-based startup Sonio for approximately 92.7 million KRW.
– Sonio has developed AI-powered software to assist obstetricians and gynecologists in ultrasound exams and has received regulatory clearance from the US FDA.
– The acquisition will enhance Samsung Medison’s AI-driven imaging capabilities and improve prenatal ultrasound examinations.
– Sonio will continue to operate independently as a company and will collaborate with Samsung Medison to advance medical reporting technology and diagnostic software globally.
Why it Matters
The acquisition of Sonio by Samsung Medison signifies the company’s commitment to improving the quality of healthcare through advanced technology. By integrating Sonio’s AI-powered software into its imaging devices, Samsung Medison aims to revolutionize the field of prenatal ultrasound examinations. This acquisition not only enhances Samsung Medison’s capabilities but also allows Sonio to access the resources and support needed for further growth and expansion.
FAQ
1. What does Sonio specialize in?
Sonio is a startup that develops AI-powered software for ultrasound workflows, specifically targeting obstetricians and gynecologists.
2. How will the acquisition benefit Samsung Medison?
The acquisition will enhance Samsung Medison’s AI-driven imaging capabilities, allowing them to offer better AI-driven imaging workflows to the market and bring a paradigm shift in prenatal ultrasound exams.
3. Will Sonio continue to operate independently after the acquisition?
Yes, Sonio will remain an independent company and will continue to offer products and services in France, collaborating with Samsung Medison to further advance medical reporting technology and diagnostic software globally.
Source Link: https://techcrunch.com/2024/05/07/samsung-medison-to-aqcuire-french-ai-ultrasound-startup-sonio-for-92-7m/